4.8 Article

Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion

出版社

NATL ACAD SCIENCES
DOI: 10.1073/pnas.2012197117

关键词

SARS-CoV-2; interferon; virus entry; COVID-19; innate immunity

资金

  1. NIH Digestive Diseases Research Core Center Grants [P30 DK052574, R00 AI135031, R01 AI150796]
  2. COVID-19 Fast Grants Funding
  3. Harvard Virology Program, NIH training Grant [T32 AI07245]
  4. NIH [75N93019C00062, R01 AI127828]
  5. Defense Advanced Research Project Agency [HR001117S0019]
  6. Washington University School of Medicine in St. Louis
  7. Helen Hay Whitney Foundation postdoctoral fellowship
  8. Biotechnology and Biological Sciences Research Council [BB/L001942/1]
  9. [R37 AI059371]
  10. [GM130386]
  11. BBSRC [BB/L001942/1] Funding Source: UKRI

向作者/读者索取更多资源

Cholesterol 25-hydroxylase (CH25H) is an interferon (IFN)-stimulated gene that shows broad antiviral activities against a wide range of enveloped viruses. Here, using an IFN-stimulated gene screen against vesicular stomatitis virus (VSV)-SARS-CoV and VSV-SAR-S-CoV-2 chimeric viruses, we identified CH25H and its enzymatic product 25-hydroxycholesterol (25HC) as potent inhibitors of SARS-CoV-2 replication. Internalized 25HC accumulates in the late endosomes and potentially restricts SARS-CoV-2 spike protein catalyzed membrane fusion via blockade of cholesterol export. Our results highlight one of the possible antiviral mechanisms of 25HC and provide the molecular basis for its therapeutic development.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据